Key Takeaways
- Strong debut quarter as a public company: Revenue grew 15% YoY and EBITDA margin expanded 110 bps to 28%, driven by CDMO/CRO momentum and operating leverage.
- Supply-chain diversification is a structural tailwind: Pharma’s long-term decision to diversify from China, accelerated by the Biosecure Act, is pulling molecules into India earlier in the development cycle, and Sai has already tech-transferred over 15 products from other geographies.
- Discovery recovery remains a known unknown: While demand from large pharma is robust, new biotech company formation has slowed and management called the recovery timeline “your guess as good as mine,” making the CRO segment’s near-term trajectory uncertain.
- Margins have room to run but investment is non-negotiable: EBITDA margin hit 28% in Q3 and management targets 28–30% steady state, but the nature of the industry demands continuous capacity investment with 18–24 month gestation, which will keep asset turns in check.
- What to watch next quarter: Whether the couple of products with PDUFA dates commercialize by year-end, the pace of molecule pipeline conversion from China-sourced development assets, and any signal on biotech funding recovery.
Demand Environment & Supply-Chain Diversification
- Biosecure Act as accelerant, not origin: Pharma’s deleveraging from China began post-COVID; the Biosecure Act pushed it in the right direction and nobody seems to be going slower, with pharma building relationships on a 5–10 year horizon.
- Earlier-stage assets now moving: Historically, late-phase molecules developed in China came to India as a secondary source; Sai is now seeing both late-phase and more Phase 1 to Phase 3 assets moving much earlier than post-COVID, which plays to its strength in development.
- China pricing pressure absorbed: China has been more aggressive on pricing, but Sai has not dropped pricing and continues to grow at a 2–3% annual increase for most customers.
- GLP-1 traction emerging: A big shift in GLP-1 across all pharma companies means anybody in CDMO will see traction in peptides, building blocks, and pure small molecules; Sai has clinical assets in that space.
Krishna Kanumuri: "I think pharma has made a long-term decision to kind of diversify from China. It's just a question of customer concentration. I think this deleveraging started back in post-COVID. I think Biosecure probably just pushed it in the right direction. I think nobody seems to be going any slower."
Financial Performance & Margin Walk
- Revenue and profitability: Q3 FY25 revenue grew 15% YoY; PAT grew 36% driven by revenue growth, cost management, and stable finance costs.
- Nine-month margin recovery: EBITDA margin improved 700 bps to 24% from 17% in the same period last year; gross margin improved to approximately 73% from 69%.
- Employee cost context: The 9% rise in employee costs reflects increased billable headcount in discovery and continued talent investment; with 40% of the business in CRO and a large development piece within CDMO, employee is the biggest capital employed and costs are not directly comparable to a pure-play CMO.
- Overseas sites turn profitable: Boston and Manchester sites are no longer a drag on profitability for Q3 or the nine-month numbers.
- Finance costs and debt: Finance costs were stable at ₹23 cr; ₹585 cr of debt was repaid from IPO proceeds as of December, with the remaining repaid in January, which will reduce interest costs going forward.
- Seasonality holds: H2 is generally stronger than H1, and Q4 has historically been the strongest quarter; management expects this pattern to hold.
Capacity, Capex & the Investment Cycle
- Capacity additions underway: 100 KL of manufacturing capacity was added in November; another 100 KL is expected in Q1 FY26.
- Land bank expanded: Land acquisition completed last quarter doubled the land area for the Hyderabad research centre, added a new Hyderabad manufacturing site, and added land in Bidar for footprint expansion.
- The asset-turn tradeoff: Investment in any asset takes 18–24 months before even 1% utilization; underutilization is factored in and is the nature of the industry because customers need to see a facility up and running to commit business.
- Capex outlook: An additional ₹100–125 cr is expected in Q4 FY25; plans for FY26 are in detailed planning and will be shared after finalization, with funding through a combination of internal accruals and debt.
- Discovery R&D expanded: Hyderabad discovery R&D capacity expanded by 15% with the addition of lab spaces for chemistry and biology.
Siva Chittor: "If you do not invest in the shorter term, our overall growth rate over long term will suffer. While we will be able to continue to show a better ROCE, we will not be able to show growth and revenue on a consistent basis."
Discovery Business & Biotech Funding
- Large pharma demand robust, biotech formation slow: Biotech funding is flowing into later-phase programs, but new company formation has slowed and the timing of recovery is uncertain; demand from larger players remains robust and increased focus on large pharma customers helps offset shorter-term funding issues.
- CRO visibility reasonable: Management is seeing a reasonable growth trend in CRO, reflected in current-year numbers, though the funding environment is not fully back to COVID levels.
Krishna Kanumuri: "Time frame is hard to judge. It's your guess as good as mine in terms of when new Company formation is going to start."
Pipeline & Commercialization
- Molecule pipeline shifting: Many molecules tech-transferred from China are now reaching the phase where they are independently scaling up; Sai is seeing a significant increase in traction from development-stage compounds coming from large pharma moving to India.
- Commercial molecule base: 38 products going to 31 molecules, with some molecules having two intermediates.
- Near-term commercialization visibility: A couple of products are expected to commercialize by the end of this financial year based on PDUFA dates; one large molecule in Phase 3 is expected to commercialize in the FY26–27 timeframe; at least three or four molecules are expected to commercialize overall.
- No near-term patent cliff exposure: No molecule from the partner side is expected to go off-patent next year.
- Schrodinger collaboration expanding: The collaboration is going very well and has been expanded, with the number of scientists growing, though management is not at liberty to share specifics.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Long-term revenue CAGR | 15–20% CAGR | Over 3–5 year blocks |
| EBITDA margin target | 28–30% steady state | Next 2–3 years |
| ROCE aspiration | Mid to high teens | Over 3–4 year period |
| Capacity addition | Another 100 KL manufacturing capacity | Q1 FY26 |
| Q4 FY25 capex | Additional ₹100–125 cr | Q4 FY25 |
| Commercialization | Couple of products based on PDUFA dates | By end of FY25 |
| Commercialization | One large Phase 3 molecule | FY26–27 timeframe |
| 15–20% CAGR baseline | Can be factored from FY26 onwards | FY26 onwards |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue from operations | ₹440 cr, +15% YoY vs ₹384 cr in Q3 FY24 |
| CDMO revenue share | 60% of total revenue |
| CRO revenue share | 40% of total revenue |
| EBITDA margin | 28%, up from 27% in Q3 FY24, +110 bps YoY |
| Profit after tax | ₹54 cr, +36% YoY vs ₹40 cr in Q3 FY24 |
| Profit before tax | ₹72 cr, +35% YoY vs ₹53 cr in Q3 FY24 |
| Earnings per share | ₹2.9, +32% YoY vs ₹2.2 in Q3 FY24 |
| Employee cost | ₹133 cr, +9% YoY vs ₹122 cr in Q3 FY24 |
| Finance costs | ₹23 cr, stable vs ₹23 cr in Q3 FY24 |
| 9M FY25 total income | ₹1,142 cr, +9% YoY vs ₹1,052 cr |
| 9M FY25 EBITDA margin | 24%, +700 bps YoY vs 17% |
| 9M FY25 gross margin | ~73%, up from 69% in prior period |
| 9M FY25 operating cash flow | ₹246 cr, 92% of EBITDA for the period |
| 9M FY25 free cash flow | ₹21 cr positive |
| 9M FY25 capex | ₹300 cr |
| Average capacity utilization (9M FY25) | 65% |
| Manufacturing capacity added | 100 KL in November 2024, another 100 KL expected in Q1 FY26 |
| Discovery R&D capacity expansion | 15% increase in Hyderabad lab spaces |
| IPO debt repayment | ₹585 cr repaid of planned ₹720 cr as of Dec 2024, remaining repaid in January 2025 |
| Commercial molecules supplied | 31 molecules |
| Products tech-transferred from other geographies | 15 products as part of supply chain diversification |
| Phase 3 pipeline | 8 to 10 products |
| Long-term revenue CAGR aspiration | 15–20% over 3–5 year blocks |
| Long-term EBITDA margin aspiration | 28–30%, expected in 2–3 years |
| Long-term ROCE aspiration | Mid to high teens over 3–4 years |